Parkinsonism

Unique Oscillatory Dynamics of Bicycling Examined in Parkinson's

September 25, 2017

"Abnormal ~18 Hz oscillations are implicated in the pathophysiology of freezing of gait, and suppressing them may form a key strategy in developing potential therapies," the authors write.

Gocovri Approved to Treat Dyskinesia in Patients with Parkinson's Disease

By August 28, 2017

The safety and efficacy of Gocovri was seen in two Phase 3 controlled trials in Parkinson's disease patients with dyskinesia.

Mislabeled Muscle Spasm, Parkinson's Drugs Prompt Recall

By July 28, 2017

Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.

The Puzzles That May Improve Brain Performance

July 18, 2017

"We found direct relationships between the frequency of word puzzle use and the speed and accuracy of performance on nine cognitive tasks assessing a range of aspects of function including attention, reasoning, and memory," researcher Keith Wesnes, PhD.

ALS, Parkinson's Mortality Tied to Certain Occupations

July 14, 2017

Occupations associated with higher education and income show increased mortality risk

Early Biomarker May Help Differentiate Parkinsonism Disorders

July 12, 2017

Magnetic resonance imaging (T1-weighted and diffusion-weighted imaging) with a 3-T magnetic resonance imager revealed that the Parkinson's patients had significant alterations in optic radiation connectivity distribution.

Xadago Available as Adjunct Therapy for Parkinson's Disease

By July 11, 2017

Patients taking Xadago also experienced less "off" time and better scores on a measure of motor function performed during "on" time vs. prior to treatment.

Strong Link Identified Between Parkinson's and Melanoma

July 11, 2017

The researchers found that, compared with controls, patients with Parkinson's disease had a 3.8-fold increased likelihood of having preexisting melanoma, while patients with melanoma had a 4.2-fold increased risk of developing Parkinson's disease.

Insomnia Drug May Help Patients with Disorders of Consciousness, Movement

By June 26, 2017

Researchers reviewed a total of 2,314 articles for zolpidem used to treat neurologic disorders across various databases.

FDA Fast Tracks Drug for Hallucinations Disorder in Lewy Body Dementia

By June 19, 2017

Nelotanserin is a novel once-daily oral 5HT2A inverse agonist. The 5HT2A receptor has been associated with neuropsychiatric effects, including visual hallucinations.

Low-Fat Dairy Consumption May Up Parkinson's Disease Risk

June 09, 2017

No such association seen with the consumption of full-fat dairy products

Inhaled L-dopa Meets Endpoints in Parkinson's Disease Study

By June 05, 2017

The study's primary endpoint was meaningful improvement in motor function as defined by the Unified Parkinson's Disease Rating Scale—Part III.

Apomorphine Reduces 'Off' Time in Advanced Parkinson's Disease

April 24, 2017

Study finds apomorphine cuts the time until levodopa kicks in for those with advanced disease

Add-On Medical Food Beneficial in Advanced Parkinson's Disease

By April 12, 2017

The average total motor complication score was also reduced from 8.8 at baseline to 4.2 after 12 months of add-on ultra-micronized palmitoylethanolamide.

First Consumer Genetic Health Risk Tests Get FDA Approval

By April 06, 2017

While the GHR tests may provide genetic risk information, they cannot determine a person's overall risk for developing a disease, as other factors beyond genetics (ie, environment, lifestyle) may also influence risk.

Exercise May Benefit Patients with Advanced Parkinson's Disease

March 29, 2017

Researchers compared health-related quality of life and mobility between self-reported regular exercisers and patients who did not exercise.

Dosing Recommendations Updated for Parkinson's Drug

By March 27, 2017

Fixed-dose studies, showed no added therapeutic benefit in patients with advanced stage Parkinson's disease taking daily doses >8mg/day or among those with early stage Parkinson's taking daily doses >12mg/day.

FDA Approves New Parkinson's Disease Treatment

By March 21, 2017

Data showed Xadago statistically and significantly increased "on" time without troublesome dyskinesia.

Inhaled Levodopa Shows Promise for OFF Periods in PD Patients

By February 09, 2017

Acorda Therapeutics announced statistically significant results from the Phase 3 study of CVT-301, an investigational inhaled formulation of levodopa, for the treatment of OFF periods in patients with Parkinson's disease (PD) on an oral carbidopa/levodopa regimen.

Blood Measure May Help Distinguish Atypical Parkinsonian Disorders

February 09, 2017

Measuring blood neurofilament light chain (NfL) levels may help distinguish Parkinson's disease (PD) from atypical parkinsonian disorders (APD), according to a study published onlinein Neurology.

Cognitive Stress Reduces Levodopa Effect in PD Patients

January 13, 2017

Levodopa effect significantly smaller during cognitive co-activation than during rest

Potential Treatment for Levodopa-Induced Dyskinesia Under Review

By January 06, 2017

The FDA has accepted for review the New Drug Application (NDA) for ADS-5102 (amantadine extended-release capsules; Adamas) for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.

Impact of Anticholinergic Drugs Should Be Considered in Older Patients

January 03, 2017

Anticholinergic medications are frequently prescribed to older adults, but their negative impact should be considered, according to a review published online December 23 in the Journal of Pharmacy Practice and Research.

Opicapone As Levodopa Adjunct Cuts Motor Fluctuations in PD

December 28, 2016

In Parkinson's disease, 50mg/day opicapone linked to significant reduction in mean daily off-time

Gene Mutation for Early-Onset Parkinson's Disease ID'd

November 30, 2016

Mutated GCH1 gene tied to 23 percent increased risk of Parkinson's; symptoms five years earlier

FDA to Review Treatment for Levodopa-Induced Dyskinesia

By October 27, 2016

Adamas announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, to potentially treat levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

Inhaled Version of Parkinson's Drug May Ease Symptoms Between Doses

October 13, 2016

An inhaled version of the Parkinson's drug levodopa can help when patients experience symptoms between doses of the pill form of the medication, according to a study published in the October 12 issue of Science Translational Medicine.

Research on Cell 'Self-Eating' Mechanism Earns Nobel Prize, Opens Doors to Drug Development

By October 03, 2016

The concept of autophagy emerged around the 1960s but its mechanisms had not been fully elucidated until the 1990s when Ohsumi began experimenting with baker's yeast.

Anticholinergic Agent Used for GI, Other Disorders Recalled

By September 15, 2016

Virtus announced a voluntary recall of 7 lots of Hyoscyamine Sulfate 0.125mg due to both superpotent and subpotent test results.

Requip Labeling Updated with New Warnings, Dosing Information

By September 13, 2016

The Food and Drug Administration (FDA) has approved labeling updates regarding dosage and warnings for Requip (ropinirole; GlaxoSmithKline) tablets.